Cell Therapy vs Gene Therapy: Which Regulatory Pathway in China Has Shorter Timelines?

Published: July 2026  |  Category: Biotech Regulatory Guide  |  Reading time: 12 minutes

1. Executive Summary

For foreign biotechnology companies evaluating China market entry, the choice between pursuing a cell therapy or a gene therapy regulatory pathway is one of the most consequential strategic decisions they will face. Both modalities are regulated primarily by the National Medical Products Administration (NMPA) via its drug evaluation arm, the Center for Drug Evaluation (CDE). However, the review frameworks, clinical trial approval timelines, and marketing authorization durations differ significantly between the two product categories.

This article provides a data-driven comparison of regulatory timelines for cell therapy and gene therapy in China, drawing on publicly available CDE review data, approved product benchmarks, and first-hand experience from foreign biotech applicants. We examine every stage from Investigational New Drug (IND) application submission through New Drug Application (NDA) approval, highlight priority review eligibility differences, and offer actionable strategic guidance for foreign executives planning China market entry.

2. Regulatory Landscape Overview: NMPA and CDE

China’s pharmaceutical regulatory framework has undergone rapid modernization since the 2017 ICH membership and the 2019 implementation of the Drug Administration Law revisions. The NMPA, through the CDE, now applies a risk-based classification system for advanced therapy medicinal products (ATMPs), which in China encompass both cell therapy and gene therapy products.

Critically, China does not yet have a single unified “ATMP regulation” analogous to the European Medicines Agency’s framework. Instead, cell and gene therapies are regulated under multiple overlapping guidance documents:

• Cell therapy: Primarily governed by the Technical Guidelines for Research and Evaluation of Cell Therapy Products (2021, updated 2023) and the Regulations for the Administration of Clinical Application of Medical Technologies (for certain somatic cell therapies).
• Gene therapy: Governed by the Technical Guidelines for Research and Evaluation of Gene Therapy Products (2022) and the Guidelines for Non-clinical Research of Gene Therapy Products (2023).
• Dual-use products: Genetically modified cell therapies (e.g., CAR-T, TCR-T) fall under both frameworks, creating complexity that directly impacts review timelines.

The CDE maintains separate review teams for cell therapy and gene therapy products within its Division of Biological Products. These teams have different workloads, expertise profiles, and historical approval rates, which we analyze below.

3. Classification and Definitional Differences

Understanding how Chinese regulators classify a product is the first determinant of its review timeline. The CDE distinguishes between these modalities as follows:

Cell Therapy Products

Defined as products using living cells as active pharmaceutical ingredients, including immune cells (CAR-T, TCR-T, NK, TIL), stem cells (MSC, iPSC-derived), and somatic cells. These are evaluated primarily under the biological product pathway but with additional requirements specific to cell-based active substances. Notably, autologous cell therapies are treated differently from allogeneic cell therapies, with the former generally receiving slightly faster initial reviews due to lower perceived systemic risk.

Gene Therapy Products

Defined as products that deliver genetic material to modify a patient’s cells in vivo or ex vivo. This includes AAV-based therapies, lentiviral vectors, non-viral gene delivery systems, and gene-editing products (CRISPR, TALEN, etc.). Chinese regulators consider gene therapy products as inherently higher-risk due to the durability and unpredictability of genetic modification, which translates to more stringent non-clinical data requirements and longer review cycles.

Gray Zone: Genetically Modified Cell Therapies

CAR-T and TCR-T products are classified as cell therapies in China, not gene therapies, despite containing genetic modification components. This classification is strategically beneficial for sponsors because it places them under the cell therapy review pathway, which has demonstrably shorter timelines. However, these products must still meet certain gene therapy-related data requirements, which can cause unexpected requests for additional information during review.

4. Clinical Trial Application (CTA/IND) Review Timelines

The IND (known in China as the CTA — Clinical Trial Application) review process is the most critical gate for foreign biotech firms. The CDE operates a statutory review clock of 60 working days for most drug categories, but ATMPs face additional evaluation steps that extend this timeline.

Cell Therapy IND Timelines

Based on CDE annual reports and industry data from 2022–2026, the median IND approval timeline for cell therapy products is 65–90 working days from submission to approval. Key factors include:

• Autologous CAR-T products: 55–75 working days (fastest category due to established precedents)
• Allogeneic cell therapies: 70–100 working days (additional safety data required)
• MSC-based therapies: 80–120 working days (variable due to evolving quality control standards)
• iPSC-derived products: 90–140 working days (scrutiny around tumorigenicity and heterogeneity)

Gene Therapy IND Timelines

Gene therapy IND reviews consistently take longer. The median timeline is 90–140 working days, with some complex products exceeding 180 working days if a clinical hold is issued. Breakdown by vector type:

• AAV-based therapies: 80–120 working days (most established vector, faster reviews)
• Lentiviral vector therapies: 100–150 working days (higher integration risk concerns)
• Non-viral delivery (LNP, etc.): 90–130 working days (less regulatory experience)
• CRISPR-based gene editing: 120–180 working days (novelty triggers extended review)

5. Priority Review and Breakthrough Therapy Designation

Both cell and gene therapy products can access China’s accelerated regulatory pathways, but eligibility rates differ significantly.

Breakthrough Therapy Designation (BTD)

China’s BTD program, modeled on the US FDA’s breakthrough therapy designation, provides intensive CDE guidance and rolling review. From 2020–2025:

• Gene therapies received BTD at a rate of approximately 35–40% of all IND submissions, reflecting their focus on severe genetic diseases with high unmet need.
• Cell therapies received BTD at a rate of approximately 20–25%, partly because the field is more crowded and many products target already-served oncology indications.

Priority Review for NDA

At the marketing authorization stage, priority review can shorten NDA evaluation from the standard 200 working days to as few as 80–100 working days. Gene therapy products are more likely to qualify for priority review at NDA stage (~45% eligibility) compared to cell therapy products (~30% eligibility), primarily because gene therapies more frequently target rare diseases with no existing treatment options in China.

Designated Review Track for Innovative Drugs

Both categories can access the Innovative Drug Designation (突破性治疗药物), which provides:

• Dedicated CDE project manager assignment within 30 days
• At least one pre-IND meeting with CDE (critical for foreign firms navigating first-time applications)
• Potential for conditional approval based on surrogate endpoints
• Rolling NDA submission (submit modules as they are completed)

6. Marketing Authorization (NDA/BLA) Review Timelines

The NDA (New Drug Application) — referred to as BLA for biologics in some cases — review process is where the timeline gap between cell and gene therapy narrows considerably.

Standard NDA Review Durations

The CDE’s statutory review period for NDAs is 200 working days (approximately 10 months), with an additional 20 working days for NMPA final approval. For ATMPs, actual timelines from 2020–2025 show:

• Cell therapy NDA: 180–280 working days (median ~210 days)
• Gene therapy NDA: 200–320 working days (median ~240 days)

Conditional Approval Pathway

Both modalities can leverage China’s conditional approval pathway (similar to US accelerated approval), which allows marketing authorization based on surrogate endpoints with a post-marketing confirmatory study commitment. This pathway has become increasingly popular for ATMPs:

• Cell therapy conditional approvals: 4 products approved conditionally as of mid-2026 (all CAR-T). Time from NDA submission to conditional approval: 150–200 working days.
• Gene therapy conditional approvals: 2 products approved conditionally. Time from NDA submission to conditional approval: 180–250 working days.

Post-Approval Commitments

An often-overlooked aspect of timelines: cell therapies typically face 2–4 years of post-marketing study commitments, while gene therapies face 3–5 years (or longer, depending on integration durability data requirements). This affects overall time-to-full-approval and market exclusivity planning.

7. Real-World Case Studies and Benchmarks

Cell Therapy Benchmark: Yescarta (Axicabtagene Ciloleucel)

Kite Pharma’s Yescarta, a CD19-directed CAR-T cell therapy, was the first CAR-T product approved in China (June 2021, originally approved in US in 2017). Its China timeline:

• IND submission to approval: ~75 working days
• Phase I/II trial completion to NDA submission: ~18 months (expedited by leveraging US clinical data under ICH E5/E17)
• NDA submission to approval: ~195 working days
• Total China development timeline: ~3.5 years from first IND to marketing authorization

Cell Therapy Benchmark: Carteyva (Relmacabtagene Autoleucel)

JW Therapeutics’ relma-cel (China’s first domestically developed CAR-T) achieved an even faster timeline:

• IND to conditional approval: ~30 months total
• NDA review: ~180 working days
• This set a benchmark for speed that many foreign firms now aim to match

Gene Therapy Benchmark: AAV-Based Product (Hypothetical Example)

While China has not yet approved an in vivo gene therapy drug for the domestic market as of mid-2026 (though several are under NDA review), the typical timeline based on industry experience:

• Pre-IND meeting to IND submission: 6–9 months (for foreign firms with overseas data package)
• IND review: 100–140 working days
• Phase I/II with extended safety monitoring: 24–36 months
• NDA review: 200–320 working days
• Estimated total timeline: 5–7 years from first China IND to approval

Cross-Border Data Utilization

One of the most important strategic levers for foreign biotech firms is the ability to use overseas clinical data to support China registration, under the ICH E5 (Ethnic Factors) and ICH E17 (Multi-Regional Clinical Trials) guidelines. Both cell and gene therapy applicants can use this pathway, but the CDE’s acceptance of bridging data is more predictable for cell therapies than for gene therapies, as the ethnic sensitivity analysis for genetic modification products remains an evolving regulatory science.

8. Comparison Table: Cell Therapy vs Gene Therapy in China

9. Strategic Recommendations for Foreign Firms

Based on the comparative analysis above, we offer the following strategic recommendations for foreign biotech companies evaluating China regulatory pathways:

1. Classify Your Product Strategically (Where Possible)

If your product has characteristics of both cell and gene therapy (e.g., CAR-T, genetically modified stem cells), engage CDE early through a pre-IND meeting to confirm classification. The cell therapy pathway is generally faster, but if your product can plausibly be classified as a gene therapy, you may gain advantages in BTD eligibility that offset slower initial timelines.

2. Build the China Regulatory Strategy Alongside Global Development

Do not treat China as an afterthought. Include Chinese clinical sites (under ICH E17 MRCT framework) in your global Phase II/III program. This practice can reduce NDA review timelines by 6–12 months compared to standalone China bridging studies.

3. Prepare for First-Cycle Review Completeness

The CDE issues a single round of deficiency questions (补充资料通知) after the initial review. Products that require a second round face 3–6 month delays. For gene therapies in particular, invest heavily in the non-clinical data package — especially for biodistribution, vector shedding, germline integration risk, and long-term toxicity — to avoid deficiency letters.

4. Leverage the Hainan Bo’ao Pilot Zone

Foreign cell and gene therapy products not yet approved in China can be used by patients in the Hainan Bo’ao Lecheng International Medical Tourism Pilot Zone under special policies. This can generate early Chinese clinical experience and real-world data to support formal NDA submissions, while providing early revenue to offset China market entry costs.

5. Partner with a Local CRO with CDE Experience

For both cell and gene therapy pathways, the quality of your interaction with CDE reviewers matters enormously. A local regulatory affairs partner familiar with CDE reviewer preferences — especially the specific teams handling ATMPs — can reduce IND preparation time by 30–50% and improve first-cycle approval odds.

10. Conclusion and Outlook

The choice between cell therapy and gene therapy regulatory pathways in China involves a nuanced trade-off. Cell therapies offer faster IND timelines and a more predictable regulatory path, making them the lower-risk choice for foreign firms seeking rapid China market entry. The median cell therapy IND approval timeline of 65–90 working days, combined with a total development-to-approval horizon of 3–5 years, represents the fastest route to market among all advanced therapy modalities in China.

Gene therapies, while facing longer IND timelines and higher regulatory burden, benefit from greater BTD and priority review eligibility. For products targeting rare genetic diseases with high unmet need, the accelerated pathways can meaningfully shorten the overall timeline. However, the typical 5–7 year total development timeline means that foreign gene therapy firms must plan for a longer China market horizon and higher upfront regulatory investment.

Looking ahead to 2026–2028, several developments could reshape this comparison:

• Draft ATMP unified regulation: The CDE is reportedly drafting a comprehensive ATMP regulation that would harmonize cell and gene therapy requirements. If adopted, this could reduce some gene therapy-specific burdens but may also add new cell therapy requirements.
• Expanded conditional approval: Both modalities are expected to benefit from broader application of conditional approval, potentially reducing NDA review timelines by 30–60 working days.
• MRCT data acceptance maturity: As Chinese regulators gain experience with MRCTs incorporating Chinese sites, the acceptance of overseas data for both cell and gene therapies is expected to become more predictable and streamlined.
• Cell therapy IND inflection point: With over 50 active CAR-T INDs in China as of mid-2026, the cell therapy space is becoming increasingly crowded. This may lead to higher CDE scrutiny of new cell therapy submissions, potentially lengthening timelines toward gene therapy levels over the next 2–3 years.

Foreign biotech firms should make the cell-vs-gene regulatory pathway decision based on their product’s specific characteristics, target indication, and strategic timeline — but with the clear understanding that in China’s current environment, cell therapy pathways currently offer a meaningful speed advantage at the IND stage, while gene therapy pathways offer differentiated advantages at the later stages of development.